| Metric | Value (₹ Cr) | vs Q4 FY25 |
|---|---|---|
| Revenue | 45.20 | 0.5% |
| Total Income | 45.56 | 0.6% |
| Expenditure | 51.63 | 16.3% |
| PBT | -6.06 | 780.4% |
| Net Profit | -5.58 | 1171.7% |
| OPM | 0.71% | 9.03pp |
| NPM | -12.25% | 13.40pp |
| EPS | 5.40 | 4053.8% |
Natural Capsules Ltd Reports Q1FY26 Results with 15.36% EBIDTA Margin
05 Aug 2025 · 5 Aug 2025, 06:52 am
Summary
Natural Capsules Ltd, a leading manufacturer of hard capsules shell, has announced its financial results for the quarter ended June 30, 2025. The company reported a revenue of ₹ 45.20 Cr with an EBIDTA margin of 15.36%. The capsules business remained stable with steady realisations across both domestic and export markets. The company plans to commercialise two additional production lines to capitalise on the rising demand for HPMC capsules.
Key Highlights
- 1
Revenue: ₹ 45.20 Cr
- 2
EBIDTA Margin: 15.36%
- 3
Quarter: Q1FY26
- 4
Stable quarter for capsules business
- 5
Slight moderation in gelatin prices
- 6
Robust demand for Indian HPMC capsules manufacturers
- 7
Plans to commercialise two additional production lines
- 8
Emerging signs of improvement in the operational environment for API front
- 9
Targeting achievement of average cash breakeven at the API facility for the first full year of operations
- 10
Key priorities: drive growth and restore higher profitability in the capsules business, scale up capacities in the API segment, attain cash breakeven at the API facility, and secure regulatory approvals needed to unlock opportunities in higher-margin businesses
Management Comments
MR. SUNIL MUNDRA
EXECUTIVE DIRECTOR
Q1FY26 was a stable quarter for our capsules business, characterised by steady realisations across both domestic and export markets. The quarter witnessed a slight moderation in gelatin prices, a trend that is expected to support improved profitability in the ensuing quarters. In the HPMC capsules segment, the imposition of US duties on Chinese HPMC capsules continues to create robust demand for Indian manufacturers. We are encouraged by the consistent flow of healthy enquiries and remain confident in our ability to scale up the HPMC business in the current year. To capitalise on this rising demand, we plan to commercialise two additional production lines from our ongoing capital expenditure in the coming quarters. This expansion is projected to drive topline growth and enhance the overall profitability of our capsules business.
Informational and educational content only. Not investment advice.